Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944554 · ClinicalTrials.gov registry record · Phase 4
Relapse Prevention With Varenicline
A Phase 4 study of Smoking Cessation and Substance-Related Disorders, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT00944554 is a Phase 4 study of Smoking Cessation and Substance-Related Disorders that has completed, run by Johns Hopkins University. The registered enrollment target is 104 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00944554, a Phase 4 study of Smoking Cessation and Substance-Related Disorders, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (1)
Maryland
- Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00944554
The ClinicalTrials.gov registry entry for NCT00944554 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (78% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00944554 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00944554 about?
NCT00944554 is a clinical study titled "Relapse Prevention With Varenicline". This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or pr...
What is the current status of trial NCT00944554?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2008-10. Estimated completion is 2011-05.
What conditions does trial NCT00944554 study?
This clinical trial studies the following conditions: Smoking Cessation, Substance-Related Disorders, Recurrence.
What interventions are being tested in trial NCT00944554?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00944554?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00944554 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.